Synta Pharmaceuticals Corporation

Kevin Paul Foley

Zhenjian Du

Weiwen Ying

Shijie Zhang

Dinesh U Chimmanamada

Howard P Ng

David James

Junghyun Chae

Lijun Sun

Teresa Przewloka

Hao Li

Dan Zhou

Shuzhen Qin

Chi-Wan Lee

Zachary Demko

Keizo Koya

Elena Kostik

James G Barsoum

Shoujun Chen

Jun Jiang

Yaming Wu

Christopher Borella

Takayo Inoue

Mei Zhang

Teresa Kowalczyk-Przewloka

Minghu Song

David Proia

Ronald K Blackman

Teresa Kowalczyk-Prezewloka

A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein. 

Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Triazole compounds that modulate Hsp90 activity

Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable Ris an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R. Substituent Ris defined herein.

Imidazole compounds that modulate HSP90 activity

The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating c-Met associated cancers, in a subject in need thereof.

Method for treating proliferative disorders associated with mutations in c-Met

The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating non-Hodgkin's lymphoma, in a subject in need thereof.

Method for treating non-Hodgkin's lymphoma

The invention relates to compounds of structural formula (I): 

Compounds for the treatment of proliferative disorders

Triazone compounds that modulate HSP90 activity

Triazole compounds that modulate HSP90 activity

The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating Bcr-Abl, FLT-3, EGFR, c-Kit, B-raf, and NPM-ALK associated cancers, in a subject in need thereof.

Method for treating a B-raf associated cancer with an Hsp90 inhibitor

Pyrazole compounds that modulate HSP90 activity

Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell Variable Ris an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R. Substituent Ris defined herein.

Growing community of inventors

Waltham, MA, United States of America

Kevin Paul Foley